Option Care Health, Inc. $OPCH Holdings Trimmed by Riverbridge Partners LLC

Riverbridge Partners LLC trimmed its holdings in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 22.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 984,360 shares of the company’s stock after selling 278,193 shares during the period. Riverbridge Partners LLC’s holdings in Option Care Health were worth $26,499,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Royal Bank of Canada raised its stake in shares of Option Care Health by 20.7% during the 1st quarter. Royal Bank of Canada now owns 231,161 shares of the company’s stock worth $8,078,000 after purchasing an additional 39,661 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Option Care Health by 162.6% in the first quarter. AQR Capital Management LLC now owns 41,633 shares of the company’s stock valued at $1,450,000 after acquiring an additional 25,777 shares during the period. Empowered Funds LLC bought a new stake in Option Care Health in the 1st quarter valued at $208,000. Invesco Ltd. grew its position in Option Care Health by 2.7% during the second quarter. Invesco Ltd. now owns 294,363 shares of the company’s stock worth $9,561,000 after buying an additional 7,678 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Option Care Health by 528.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,407 shares of the company’s stock worth $46,000 after purchasing an additional 1,183 shares in the last quarter. Hedge funds and other institutional investors own 98.05% of the company’s stock.

Option Care Health Trading Up 3.1%

Shares of NASDAQ OPCH opened at $21.97 on Wednesday. Option Care Health, Inc. has a 1-year low of $18.01 and a 1-year high of $36.80. The company has a market cap of $3.45 billion, a PE ratio of 17.03, a P/E/G ratio of 1.18 and a beta of 0.67. The company has a current ratio of 1.64, a quick ratio of 1.07 and a debt-to-equity ratio of 0.85. The company has a 50-day moving average of $22.77 and a two-hundred day moving average of $28.81.

Option Care Health (NASDAQ:OPCH) last announced its earnings results on Thursday, April 30th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.03. Option Care Health had a net margin of 3.64% and a return on equity of 18.17%. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.39 billion. During the same period in the prior year, the business earned $0.40 earnings per share. Option Care Health’s quarterly revenue was up 1.3% on a year-over-year basis. Option Care Health has set its FY 2026 guidance at 1.820-1.920 EPS. As a group, equities analysts expect that Option Care Health, Inc. will post 1.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on OPCH shares. Wall Street Zen cut shares of Option Care Health from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. The Goldman Sachs Group initiated coverage on Option Care Health in a report on Monday, June 8th. They issued a “neutral” rating and a $22.00 target price on the stock. TD Cowen dropped their price target on Option Care Health from $37.00 to $23.00 and set a “hold” rating for the company in a report on Friday, May 1st. Weiss Ratings downgraded Option Care Health from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 11th. Finally, Bank of America lowered Option Care Health from a “buy” rating to a “neutral” rating and set a $22.00 price objective on the stock. in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.54.

Insider Buying and Selling

In other news, Director Timothy P. Sullivan acquired 24,154 shares of Option Care Health stock in a transaction on Thursday, May 7th. The shares were purchased at an average price of $20.69 per share, with a total value of $499,746.26. Following the acquisition, the director owned 73,383 shares in the company, valued at $1,518,294.27. This represents a 49.06% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO John Charles Rademacher acquired 12,500 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was purchased at an average price of $21.18 per share, for a total transaction of $264,750.00. Following the completion of the transaction, the chief executive officer directly owned 695,152 shares in the company, valued at approximately $14,723,319.36. The trade was a 1.83% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 73,264 shares of company stock worth $1,548,316 in the last quarter. Insiders own 1.70% of the company’s stock.

About Option Care Health

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.